Interleukin-6 May Contribute to Mortality in Parkinson's Disease Patients: A 4-Year Prospective Study
| Authors | |
|---|---|
| Year of publication | 2015 |
| Type | Article in Periodical |
| Magazine / Source | Parkinsons Disease |
| MU Faculty or unit | |
| Citation | |
| Web | http://www.hindawi.com/journals/pd/2015/898192/ |
| Doi | http://dx.doi.org/10.1155/2015/898192 |
| Field | Neurology, neurosurgery, neurosciences |
| Keywords | GROWTH-FACTOR-ALPHA; C-REACTIVE PROTEIN; CEREBROSPINAL-FLUID; CYTOKINE PRODUCTION; ATHEROSCLEROSIS; INFLAMMATION; RISK; HEALTH; BRAIN; IL-6 |
| Attached files | |
| Description | Objectives. The association between abnormal serum immunomarkers and mortality in 53 consecutive Parkinson's disease patients was studied. Materials and Methods. The plasma level of specific inflammatory cytokines was investigated: mannan-binding lectin (MBL), interleukin-(IL-) 6, and tumor necrosis factor-alpha (TNF-alpha). The baseline serum immunomarkers obtained from patients who died (n = 16) during a four-year follow-up period were compared with the data of patients who survived (n = 37). Results. The baseline level of IL-6 was significantly higher in the deceased patients than in the survivors. Elevated IL-6 levels and age were major independent contributors to disease mortality. Differences between other plasma cytokine level abnormalities were not significant. Conclusion. This study showed that IL-6 elevation may be a marker of increased mortality risk in Parkinson's disease patients. The inflammation may act in association with other factors and comorbidities in progressive neurodegenerative pathology. |
| Related projects: |